CoChat

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease

Open access
Gasmi, Mehdi, Brandon, Eugene P., Herzog, Christopher D., Wilson, Alistair, Bishop, Kathie M., Hofer, Eva K., Cunningham, Justine J., Printz, Marie A., Kordower, Jeffrey H., Bartus, Raymond T. · 2007 · Neurobiology of Disease
Cited by 141

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Neurturin (NTN) is a neurotrophic factor with known potential to protect and restore the function of dopaminergic substantia nigra neurons whose degeneration has been most closely linked to the major motor deficits in Parkinson's disease (PD). CERE-120, an adeno-associated virus serotype 2 (AAV2)-based gene delivery vector encoding human NTN, is being developed as a potential therapeutic for PD. In a series of preclinical studies reported herein, CERE-120 delivery to the striatum produced a dose-related neuroprotection of nigrostriatal neurons in the rat 6-hydroxydopamine (6-OHDA) lesion model. Long-lasting efficacy of CERE-120 was evidenced by substantia nigra cell protection, preserved fiber innervation of the striatum, and behavioral recovery for at least 6 months. In addition, striatal infusion of CERE-120 was found to have a safety and tolerability profile devoid of side effects or toxicological responses, for at least 12 months post-treatment, even at dose multiples 125 times that of the lowest efficacious dose tested. These results support the ongoing CERE-120 clinical program in PD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2007.04.003

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 31

  1. Akerud, 1999, Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons, J. Neurochem., 73, 70, 10.1046/j.1471-4159.1999.0730070.x · DOI · Paper page
  2. Crystal, 2004, Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis, Human Gene Therapy, 11, 1131
  3. Dass, B., et al., submitted for publication. Dose-related transgene expression and bioactivity in the monkey nigrostriatal system following intrastriatal delivery of AAV2–Neurturin (CERE-120). Journal of Comparative Neurology.
  4. During, 2001, Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation, Hum Gene Ther., 12, 1589
  5. Eriksdotter Jonhagen, 1998, Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease, Dement. Geriatr Cogn. Disord., 9, 246, 10.1159/000017069 · DOI · Paper page
  6. Gasmi, 2007, Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease, Mol. Ther., 15, 62, 10.1038/sj.mt.6300010 · DOI · Paper page
  7. Georgievska, 2002, errant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer, Exp. Neurol., 177, 461, 10.1006/exnr.2002.8006 · DOI · Paper page
  8. Georgievska, 2004, Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system, J. Neurosci., 24, 6437, 10.1523/JNEUROSCI.1122-04.2004 · DOI · Paper page
  9. Herzog, C.D., et al., in press. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Movement Disorders (April 18, 2007, Epub ahead of print). · DOI · Paper page
  10. Hoane, 1999, Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor, Exp. Neurol., 160, 235, 10.1006/exnr.1999.7175 · DOI
  11. Horger, 1998, Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons, J. Neurosci., 18, 4929, 10.1523/JNEUROSCI.18-13-04929.1998 · DOI · Paper page
  12. Kirik, 2000, Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system, J. Neurosci., 20, 4686, 10.1523/JNEUROSCI.20-12-04686.2000 · DOI · Paper page
  13. Kordower, 1999, Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease, Ann. Neurol., 46, 419, 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q · doi:10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q
  14. Kordower, 2006, Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys, Ann. Neurol., 60, 706, 10.1002/ana.21032 · DOI · Paper page
  15. Lang, 2006, Randomized controlled trial of intraputamenal glial cell line- derived neurotrophic factor infusion in Parkinson disease, Ann. Neurol., 59, 459, 10.1002/ana.20737 · DOI · Paper page
  16. Love, 2005, Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain, Nat. Med., 11, 703, 10.1038/nm0705-703 · DOI · Paper page
  17. Mandel, 1997, Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats, Proc. Natl. Acad Sci. U. S. A., 94, 14083, 10.1073/pnas.94.25.14083 · DOI · Paper page
  18. Mandel, 1999, Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson’s disease, Exp. Neurol., 160, 205, 10.1006/exnr.1999.7203 · DOI
  19. McBride, 2002, Neuroprotection for Parkinson’s disease using viral vector-mediated delivery of GDNF, Prog. Brain Res., 138, 421, 10.1016/S0079-6123(02)38091-9 · DOI
  20. McCown, 2005, Adeno-associated virus (AAV) vectors in the CNS, Curr Gene Ther., 5, 333, 10.2174/1566523054064995 · DOI · Paper page
  21. Nutt, 2003, Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD, Neurology, 60, 69, 10.1212/WNL.60.1.69 · DOI · Paper page
  22. Oiwa, 2002, Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease, Brain Res., 947, 271, 10.1016/S0006-8993(02)02934-7 · DOI
  23. Rosenblad, 1998, Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson’s disease, Neuroscience, 82, 129, 10.1016/S0306-4522(97)00269-8 · DOI
  24. Rosenblad, 1999, Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle, Eur. J. Neurosci., 11, 1554, 10.1046/j.1460-9568.1999.00566.x · DOI · Paper page
  25. Rosenblad, 2003, Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system, Eur. J. Neurosci., 17, 260, 10.1046/j.1460-9568.2003.02456.x · DOI · Paper page
  26. Salvatore, 2006, Point source concentration of GDNF may explain failure of Phase II clinical trial, Exp. Neurol., 202, 497, 10.1016/j.expneurol.2006.07.015 · DOI · Paper page
  27. Sherer, 2006, Crossroads in GDNF therapy for Parkinson’s disease, Mov. Disord., 21, 136, 10.1002/mds.20861 · DOI · Paper page
  28. Slevin, 2005, Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor, J. Neurosurg., 102, 216, 10.3171/jns.2005.102.2.0216 · DOI · Paper page
  29. Tseng, 1998, Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy, NeuroReport, 9, 1817, 10.1097/00001756-199806010-00027 · DOI · Paper page
  30. Ungerstedt, 1970, Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system, Brain Res., 24, 485, 10.1016/0006-8993(70)90187-3 · DOI · Paper page
  31. Wang, 2002, Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson’s disease, Gene Ther., 9, 381, 10.1038/sj.gt.3301682 · DOI

Cited by

See all 141

Metadata

Authors
Gasmi, M., Brandon, E. P., Herzog, C. D., Wilson, A., Bishop, K. M., Hofer, E. K., Cunningham, J. J., Printz, M. A., Kordower, J. H., & Bartus, R. T.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2007-07
Volume
27
Issue
1
Pages
67-76
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2086480069
Cited by
141
References
6
FWCI
9.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease. https://app.cochat.ai/papers/10.1016/j.nbd.2007.04.003
The paper
Gasmi, M., Brandon, E. P., Herzog, C. D., Wilson, A., Bishop, K. M., Hofer, E. K., Cunningham, J. J., Printz, M. A., Kordower, J. H., & Bartus, R. T. (2007). AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2007.04.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.